| Morphea and eosinophilic fasciitis: an update JS Mertens, MMB Seyger, RM Thurlings, TRDJ Radstake, EMGJ de Jong American journal of clinical dermatology 18, 491-512, 2017 | 145 | 2017 |
| Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric‐or adult‐onset disease JS Mertens, MMB Seyger, W Kievit, E Hoppenreijs, TLTA Jansen, ... British Journal of Dermatology 172 (3), 722-728, 2015 | 78 | 2015 |
| Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis E Chouri, NH Servaas, CPJ Bekker, AJ Affandi, M Cossu, MR Hillen, ... Journal of Autoimmunity 89, 162-170, 2018 | 77 | 2018 |
| Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome LL van den Hoogen, JAG van Roon, JS Mertens, J Wienke, AP Lopes, ... Annals of the rheumatic diseases 77 (12), 1810-1814, 2018 | 75 | 2018 |
| Galectin‐9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation J Wienke, F Bellutti Enders, J Lim, JS Mertens, LL van den Hoogen, ... Arthritis & Rheumatology 71 (8), 1377-1390, 2019 | 60 | 2019 |
| Tissue‐resident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis EF Leijten, TS van Kempen, MA Olde Nordkamp, JN Pouw, ... Arthritis & Rheumatology 73 (7), 1220-1232, 2021 | 53 | 2021 |
| Oral R115866 in the treatment of moderate to severe plaque‐type psoriasis CJ Verfaille, C Thissen, HJ Bovenschen, J Mertens, PM Steijlen, ... Journal of the European Academy of Dermatology and Venereology 21 (8), 1038-1046, 2007 | 47 | 2007 |
| Use of mycophenolate mofetil in patients with severe localized scleroderma resistant or intolerant to methotrexate JS Mertens, D Marsman, PCM van de Kerkhof, EPAH Hoppenreijs, ... | 46 | 2016 |
| Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and Sjögrens syndrome M van der Kroef, LL van den Hoogen, JS Mertens, SLM Blokland, ... European journal of immunology 50 (1), 119-129, 2020 | 44 | 2020 |
| Oral R115866 in the treatment of moderate to severe facial acne vulgaris: an exploratory study CJ Verfaille, M Coel, IH Boersma, J Mertens, M Borgers, D Roseeuw British Journal of Dermatology 157 (1), 122-126, 2007 | 41 | 2007 |
| Low RUNX3 expression alters dendritic cell function in patients with systemic sclerosis and contributes to enhanced fibrosis AJ Affandi, T Carvalheiro, A Ottria, JCA Broen, L Bossini-Castillo, ... Annals of the rheumatic diseases 78 (9), 1249-1259, 2019 | 27 | 2019 |
| Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk J Wienke, JS Mertens, S Garcia, J Lim, CA Wijngaarde, JG Yeo, A Meyer, ... Rheumatology 60 (2), 785-801, 2021 | 21 | 2021 |
| Drug survival and predictors of drug survival for methotrexate treatment in a retrospective cohort of adult patients with localized scleroderma JS Mertens, J van den Reek, W Kievit, PCM van de Kerkhof, RM Thurlings, ... | 21 | 2016 |
| Induction of inflammation and fibrosis by semaphorin 4A in systemic sclerosis T Carvalheiro, AJ Affandi, B Malvar‐Fernández, I Dullemond, M Cossu, ... Arthritis & Rheumatology 71 (10), 1711-1722, 2019 | 20 | 2019 |
| The identification of CCL18 as biomarker of disease activity in localized scleroderma JS Mertens, E de Jong, LL van Den Hoogen, J Wienke, RM Thurlings, ... Journal of Autoimmunity 101, 86-93, 2019 | 20 | 2019 |
| High-dose intravenous pulse methotrexate in patients with eosinophilic fasciitis JS Mertens, MC Zweers, W Kievit, HKA Knaapen, M Gerritsen, ... JAMA dermatology 152 (11), 1262-1265, 2016 | 20 | 2016 |
| Long-term outcome of eosinophilic fasciitis: a cross-sectional evaluation of 35 patients JS Mertens, RM Thurlings, W Kievit, MMB Seyger, TRD Radstake, ... Journal of the American Academy of Dermatology 77 (3), 512-517. e5, 2017 | 14 | 2017 |
| Regarding" transcriptional and cytokine profiles identify CXCL9 as a biomarker of disease activity in morphea" JS Mertens, E de Jong, A Pandit, MMB Seyger, E Hoppenreijs, ... The Journal of investigative dermatology 138 (5), 1212-1215, 2018 | 11 | 2018 |
| Galectin-9 reflects the interferon signature and correlates with disease activity in systemic autoimmune diseases. Response to:‘Biomarkers: to be or not to be’by Yavuz and Rönnblom LL Van Den Hoogen, EHM Van Der Heijden, MR Hillen, JS Mertens, ... Annals of the Rheumatic Diseases 79 (1), e9-e9, 2020 | 9 | 2020 |
| Beliefs about medicines in patients with psoriasis treated with methotrexate or biologics: A cross-sectional survey study ME Otero, JMPA Van Den Reek, PCM van de Kerkhof, JS Mertens, ... | 9 | 2019 |
Timothy RadstakeHead Early Immunology Discovery Research, AbbvieBestätigte E-Mail-Adresse bei abbvie.com
